FDA Webview
X
about-us-banner

FDA Related News

Home / Articles / FDA Related News
Human Drugs

Novartis sBLA for Ofatumumab in Multiple Sclerosis

FDA extends by three months its review of a Novartis supplemental BLA for ofatumumab (OMB 157), a self-administered, targeted B-cell therapy for patie...

Federal Register

Product-specific Bioequivalence Guidances Available

Federal Register notice: FDA posts additional draft and revised draft product-specific guidances on bioequivalence study designs to support ANDAs.

Human Drugs

Informed Consent App for Researchers

FDA makes the Covid MyStudies app available for investigators to use to obtain informed consent electronically.

Medical Product Trials During Emergency

FDA issues an immediately effective guidance on conducting clinical trials of medical products during the current public health emergency.

Medical Devices

Welldoc 510(k) for BlueStar Insulin Adjustment

FDA clears a Welldoc 510(k) to add a new feature to its digital health product BlueStar Rx which supports individuals using long-acting insulin.

Human Drugs

FDA Drug Competition Plan Hurts Investors: Motley Fool

The Motley Fool says FDAs drug competition initiative to promote generic drugs is good for consumers but can hurt some investors.

Medical Devices

Noctrix Breakthrough Device for Restless Legs Syndrome

FDA grants Noctrix Health a Breakthrough DevicR-CASEe Designation for its wearable NTX100 neuromodulation therapy designed for treating adults with re...

Human Drugs

New Diabetes Draft Guidance is Step Backward: Professor

Two stakeholders comment on an FDA draft guidance on evaluating the safety of new drugs for improving glycemic control.

Human Drugs

Physician Group Sues FDA for Hydroxychloroquine Access

The Association of American Physicians and Surgeons files suit against FDA in western Michigan federal court to force the agency to stop limiting acce...

Human Drugs

Modeling Tools to Aid Generic Drug Development

An FDA Regulatory Science Impact Story article touts the use of quantitative methods and modeling to modernize generic drug development.